Trypanosomiasis afflicts about 6~7 million people globally and to a large extent impedes livestock production in Africa.Naturally,trypanosomal parasites undergo genetic mutation and have developed resistance over a wi...Trypanosomiasis afflicts about 6~7 million people globally and to a large extent impedes livestock production in Africa.Naturally,trypanosomal parasites undergo genetic mutation and have developed resistance over a wide range of therapies.The utilization of animals and plants products has presented therapeutic potential for identifying novel anti-trypanosomal drugs.This study evaluated toad venom for anti-trypanosomal potency in-vivo in Swiss mice.Toads were collected from July to August 2019.The acute oral toxicity and biochemical characterization of the toad venom were determined.The experimental mice were administered various doses(130 mg/kg,173 mg/kg and 217 mg/kg)of the toad venom crude extract and 0.75 mg/mL of Diamizan Plus standard drug for the treatment of trypanosomiasis,once daily for 3 days.The in-vivo anti-trypanosomal activity was evaluated by a curative test,after infecting the mice with Trypanosoma brucei brucei.The pre-patent period was 72 hours before treatment commenced.The overall results showed that trypanosomal load was highest in the control group while the group treated with Diamizan drug had the least trypanosomal load.As such,the mean trypanosomal load in relation to treatments showed a very high significant difference(P<0.05).Also,the mean trypanosomal load in Swiss mice in relation to the highest dosage of toad venom versus Diamizan drug showed a very high significant difference(P<0.05).The mean change in relation to the haematological parameters across treatments groups varied significantly(P<0.05)with the exception of Hb which showed no significant difference(P>0.05)across treatment groups.The over 50%reduction in the trypanosomal load in the 130 mg/kg group in comparison with the control group brings to bare the anti-trypanosomal potency of the toad venom.The anti-trypanosomal activity demonstrated by the toad venom has provided basis for development of new therapeutic agents from different toad species.The study recommends further studies(both in-vivo and in-vitro)followed by the characterization of the active compounds present in the toad venom responsible for the anti-tyrpanosomal activity observed alongside the management and conservation of these species.展开更多
Marinobufagenin(MBG)is a bufadienolide compound belonging to the cardiac glycosides class.The bufadienolides are present in humans as well as in some plants and animals.But the major source for these compounds is loca...Marinobufagenin(MBG)is a bufadienolide compound belonging to the cardiac glycosides class.The bufadienolides are present in humans as well as in some plants and animals.But the major source for these compounds is located in the parotid and skin gland secretions of some toad species.MBG is acting as a human endogenous cardiac inotrope and is demonstrating展开更多
目的探讨醇溶性蟾蜍毒素对S180荷瘤小鼠肉瘤细胞Mg2+-ATP酶(Mg2+-ATPase)、葡萄糖-6-磷酸酶(G-6-Pase)活性的影响。方法乙醇溶解蟾蜍分泌物原浆,采用减压蒸馏等方法,进一步部分分离纯化,获得醇溶性的蟾蜍毒素混合物(Ethanol extract of ...目的探讨醇溶性蟾蜍毒素对S180荷瘤小鼠肉瘤细胞Mg2+-ATP酶(Mg2+-ATPase)、葡萄糖-6-磷酸酶(G-6-Pase)活性的影响。方法乙醇溶解蟾蜍分泌物原浆,采用减压蒸馏等方法,进一步部分分离纯化,获得醇溶性的蟾蜍毒素混合物(Ethanol extract of toad venom,简称EET),将其作用于S180荷瘤小鼠模型,计算肿瘤抑制率,应用酶化学染色法观察S180肉瘤细胞酶活性的变化。结果蟾蜍毒素组和氟脲嘧啶组的肿瘤抑制率分别为35.6%和36.9%(P<0.05),细胞质膜标志酶Mg2+-ATPase、内质网标志酶G-6-Pase反应颗粒变小,数量减少,密度变低,提示酶活性明显下降。结论蟾蜍毒素可降低S180荷瘤小鼠肉瘤细胞质膜标志酶Mg2+-AT-Pase及内质网标志酶G-6-Pase的活性,抑制肿瘤细胞的生长。展开更多
文摘Trypanosomiasis afflicts about 6~7 million people globally and to a large extent impedes livestock production in Africa.Naturally,trypanosomal parasites undergo genetic mutation and have developed resistance over a wide range of therapies.The utilization of animals and plants products has presented therapeutic potential for identifying novel anti-trypanosomal drugs.This study evaluated toad venom for anti-trypanosomal potency in-vivo in Swiss mice.Toads were collected from July to August 2019.The acute oral toxicity and biochemical characterization of the toad venom were determined.The experimental mice were administered various doses(130 mg/kg,173 mg/kg and 217 mg/kg)of the toad venom crude extract and 0.75 mg/mL of Diamizan Plus standard drug for the treatment of trypanosomiasis,once daily for 3 days.The in-vivo anti-trypanosomal activity was evaluated by a curative test,after infecting the mice with Trypanosoma brucei brucei.The pre-patent period was 72 hours before treatment commenced.The overall results showed that trypanosomal load was highest in the control group while the group treated with Diamizan drug had the least trypanosomal load.As such,the mean trypanosomal load in relation to treatments showed a very high significant difference(P<0.05).Also,the mean trypanosomal load in Swiss mice in relation to the highest dosage of toad venom versus Diamizan drug showed a very high significant difference(P<0.05).The mean change in relation to the haematological parameters across treatments groups varied significantly(P<0.05)with the exception of Hb which showed no significant difference(P>0.05)across treatment groups.The over 50%reduction in the trypanosomal load in the 130 mg/kg group in comparison with the control group brings to bare the anti-trypanosomal potency of the toad venom.The anti-trypanosomal activity demonstrated by the toad venom has provided basis for development of new therapeutic agents from different toad species.The study recommends further studies(both in-vivo and in-vitro)followed by the characterization of the active compounds present in the toad venom responsible for the anti-tyrpanosomal activity observed alongside the management and conservation of these species.
文摘Marinobufagenin(MBG)is a bufadienolide compound belonging to the cardiac glycosides class.The bufadienolides are present in humans as well as in some plants and animals.But the major source for these compounds is located in the parotid and skin gland secretions of some toad species.MBG is acting as a human endogenous cardiac inotrope and is demonstrating
文摘目的对蟾酥(Venenum Bufonis)中吲哚烷胺类生物碱进行提取分离和结构鉴定。方法蟾酥水溶性部分经HP 20树脂柱,制备薄层色谱,高效液相色谱分离和精制,得到6个吲哚烷胺生物碱,通过理化常数和光谱数据,分析鉴定了其化学结构。结果蟾酥水提取物中分离得到6个生物碱,分别鉴定为蟾毒色胺(bufotenine,Ⅰ)、蟾毒色胺内盐(bufotenidine,Ⅱ)b、ufobutanoic acid(Ⅲ)、5羟色胺(serotonin,Ⅳ)b、ufotenine N oxide(Ⅴ)、N甲基5羟色胺(Ⅵ)。结论化合物Ⅴ和Ⅵ为首次从蟾酥中分离得到。首次对蟾酥色胺内盐及bufotenine N oxide的1H1、3C NMR数据进行归属。
文摘目的探讨醇溶性蟾蜍毒素对S180荷瘤小鼠肉瘤细胞Mg2+-ATP酶(Mg2+-ATPase)、葡萄糖-6-磷酸酶(G-6-Pase)活性的影响。方法乙醇溶解蟾蜍分泌物原浆,采用减压蒸馏等方法,进一步部分分离纯化,获得醇溶性的蟾蜍毒素混合物(Ethanol extract of toad venom,简称EET),将其作用于S180荷瘤小鼠模型,计算肿瘤抑制率,应用酶化学染色法观察S180肉瘤细胞酶活性的变化。结果蟾蜍毒素组和氟脲嘧啶组的肿瘤抑制率分别为35.6%和36.9%(P<0.05),细胞质膜标志酶Mg2+-ATPase、内质网标志酶G-6-Pase反应颗粒变小,数量减少,密度变低,提示酶活性明显下降。结论蟾蜍毒素可降低S180荷瘤小鼠肉瘤细胞质膜标志酶Mg2+-AT-Pase及内质网标志酶G-6-Pase的活性,抑制肿瘤细胞的生长。
